Cor Vasa 2007, 49(3):K73

Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti, vypracované výborem České společnosti pro aterosklerózu

Published: March 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti, vypracované výborem České společnosti pro aterosklerózu. Cor Vasa. 2007;49(3):K73.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cífková R, Býma S, Češka R, a spol. Prevence kardiovaskulárních onemocnění v dospělém věku. Společné doporučení českých odborných společností. Vnitř Lék 2005;51:1021-36.
    2. Neaton JD, Blackburn H, Jacobs D, et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992;152:1490-500. Go to original source...
    3. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-9. Go to original source... Go to PubMed...
    4. Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998;19 Suppl A:A2-A11. Go to original source... Go to PubMed...
    5. The Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64. Go to original source...
    6. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialist (CTT) Collaborators. Efficacy and safety of cholesterol lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005;366:1267-78. Go to original source... Go to PubMed...
    7. Castelli WP, Garrison RJ, Wilson PWF, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study. JAMA 1986;256:2835. Go to original source... Go to PubMed...
    8. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4 444 pateints with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994:334:1383-9. Go to original source...
    9. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Prevention Study Group. New Engl J Med 1995;333:1301-7. Go to original source... Go to PubMed...
    10. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl J Med 1998;339: 1349-57. Go to original source...
    11. Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5 963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16. Go to original source...
    12. Colhoun HM, Betteridge DJ, Durrington PN, et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96. Go to original source... Go to PubMed...
    13. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New Engl J Med 2004; 350:1495-504. Go to original source... Go to PubMed...
    14. Nissen SE, Tuzcu EM, Schoenhagen P, et al. REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on pregression of coronary atherosclerosis. A randomized controlled trial. JAMA 2004; 291:1071-80 Go to original source... Go to PubMed...
    15. Sever PS, Dahlof B, Poulter NR, et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patiens who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003;361:1149-58. Go to original source... Go to PubMed...
    16. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New Engl J Med 2005;352:1425-35. Go to original source... Go to PubMed...
    17. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis: The ASTEROID Trial. JAMA 2006; 295:1556-65. Go to original source... Go to PubMed...
    18. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-33. Go to original source... Go to PubMed...
    19. Walldius G, Jungner I. The apoB/apoA-1 ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. J Intern Med 2006;259:493-519. Go to original source... Go to PubMed...
    20. Barter PJ, Ballantyne CM, Carmena R, et al. Apo B versus cholesterol in estimating cardiovascular risk and in quiding therapy: report of the thirty-person/ten country panel. J Intern Med 2006;259:247-58. Go to original source... Go to PubMed...
    21. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97. Go to original source... Go to PubMed...
    22. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2004;364:937-52. Go to original source... Go to PubMed...
    23. Conroy R, Pyörälä K, Fitzgerald A, et al. Prediction of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003. Go to original source... Go to PubMed...
    24. O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. New Engl J Med 1999;340:14-22. Go to original source... Go to PubMed...
    25. Budoff MJ, Achenbach S, Blumenthal RS, et al. Assessment of Coronary Artery Disease by Cardiac Computed Tomography. A Scientific Statement From the American Heart Association Committee on Cardiovascular Imaging and Intervention. Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging. Council on Clinical Cardiology. Circulation 2006;114: 1761-91. Go to original source... Go to PubMed...
    26. Naghavi M, Falk E, Hecht HS, et al for the SHAPE Task Force; From Vulnerable Plaque to Vulnerable Patient - Part III: Executive Summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force Report. Am J Cardiol 2006;98 Suppl:2H-15H. Go to original source... Go to PubMed...
    27. Grundy SM, Cleenam JI, Bairey CN, et al. Implication of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-39. Go to original source... Go to PubMed...
    28. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006; 48:438-45. Go to original source... Go to PubMed...
    29. Králíková E, Býma S, Cífková R, a spol. Doporučení pro léčbu závislosti na tabáku. Čas Lék čes 2005;144:327-33.
    30. Grundy SM. Dietary influences on serum lipids and lipoproteins. J Lipid Res 1990;31:1149-72. Go to original source...
    31. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. New Engl J Med 1999;341:410-8. Go to original source... Go to PubMed...
    32. Keech A, Simes RJ, Barter P, et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005;366:1849-61. Go to original source... Go to PubMed...
    33. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. New Engl J Med 2001; 345:1583-92. Go to original source... Go to PubMed...
    34. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:567-72. Go to original source...
    35. Pearson TA, Mensah GA, Wayne AR, et al. Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and American Heart Association. Circulation 2003;107:499-511. Go to original source... Go to PubMed...
    36. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000;102:1082-5. Go to original source...
    37. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowerin and cardiovascular events after acute myocardial infarction. New Engl J Med 2006;354:1578-88. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes